[go: up one dir, main page]

DE3687099D1 - Verwendung von einem cartilago-induzierenden faktor (cif) zur herstellung eines arzneimittels zur behandlung von entzuendungen. - Google Patents

Verwendung von einem cartilago-induzierenden faktor (cif) zur herstellung eines arzneimittels zur behandlung von entzuendungen.

Info

Publication number
DE3687099D1
DE3687099D1 DE8686306000T DE3687099T DE3687099D1 DE 3687099 D1 DE3687099 D1 DE 3687099D1 DE 8686306000 T DE8686306000 T DE 8686306000T DE 3687099 T DE3687099 T DE 3687099T DE 3687099 D1 DE3687099 D1 DE 3687099D1
Authority
DE
Germany
Prior art keywords
cif
cartilago
producing
medicinal product
treating inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8686306000T
Other languages
English (en)
Other versions
DE3687099T2 (de
Inventor
Hanne Bentz
Larry Ellingsworth
Rosa Armstrong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Collagen Aesthetics Inc
Original Assignee
Collagen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Collagen Corp filed Critical Collagen Corp
Application granted granted Critical
Publication of DE3687099D1 publication Critical patent/DE3687099D1/de
Publication of DE3687099T2 publication Critical patent/DE3687099T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/84—Bones; tendons; teeth; cartilage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DE8686306000T 1985-08-06 1986-08-04 Verwendung von einem cartilago-induzierenden faktor (cif) zur herstellung eines arzneimittels zur behandlung von entzuendungen. Expired - Fee Related DE3687099T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76333785A 1985-08-06 1985-08-06
US06/836,672 US4806523A (en) 1985-08-06 1986-03-06 Method of treating inflammation

Publications (2)

Publication Number Publication Date
DE3687099D1 true DE3687099D1 (de) 1992-12-17
DE3687099T2 DE3687099T2 (de) 1993-03-18

Family

ID=27117266

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3650499T Expired - Fee Related DE3650499T2 (de) 1985-08-06 1986-08-04 Verwendung von "Cartilage-inducing Factor" (CIF) zur Behandlung von hemato- oder lymphopoietischen Krankheiten
DE8686306000T Expired - Fee Related DE3687099T2 (de) 1985-08-06 1986-08-04 Verwendung von einem cartilago-induzierenden faktor (cif) zur herstellung eines arzneimittels zur behandlung von entzuendungen.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE3650499T Expired - Fee Related DE3650499T2 (de) 1985-08-06 1986-08-04 Verwendung von "Cartilage-inducing Factor" (CIF) zur Behandlung von hemato- oder lymphopoietischen Krankheiten

Country Status (7)

Country Link
US (2) US4806523A (de)
EP (2) EP0451439B1 (de)
JP (1) JPH0798754B2 (de)
AT (2) ATE82133T1 (de)
AU (1) AU591513B2 (de)
CA (1) CA1265445A (de)
DE (2) DE3650499T2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529982A (en) * 1985-08-06 1996-06-25 Celtrix Pharmaceuticals, Inc. Inducing granulocyte production or B cell production in peripheral blood by TGF-β
US4816442A (en) * 1986-11-07 1989-03-28 Collagen Corporation Method of inhibiting tumor growth sensitive to CIF-βtreatment
EP0269408A3 (de) * 1986-11-26 1989-08-30 Genentech, Inc. TGF-Beta für die Behandlung von entzündlichen Erkrankungen
US4931548A (en) * 1987-01-30 1990-06-05 Techne Corporation Heterodimer form of transforming growth factor-beta
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
US5221734A (en) * 1987-10-01 1993-06-22 Ciba-Geigy Corporation Process for preparing a polypeptide growth factor for milk
WO1990000900A1 (en) * 1988-07-20 1990-02-08 Amgen Inc. Method of treating inflammatory disorders by reducing phagocyte activation
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
IE61346B1 (en) * 1988-11-02 1994-11-02 Genentech Inc A permeable material to fit around the teeth or gums of a mammal
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5268455A (en) * 1989-05-25 1993-12-07 Genentech, Inc. Process for making biologically active polypeptides based on transforming growth factor-βsequences
US5118791A (en) * 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
US5422340A (en) * 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
US20030186913A1 (en) * 1990-03-21 2003-10-02 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US5147799A (en) * 1990-04-25 1992-09-15 Isia Bursuker Repopulation of macrophages and granulocytes using transforming growth factor-beta
JP2625033B2 (ja) * 1990-09-21 1997-06-25 セルトリックス ファーマシューティカルズ，インコーポレイテッド 顆粒球の産生もしくは末梢血中におけるｂ細胞の産生を誘発するための組成物
JPH06505965A (ja) * 1990-11-16 1994-07-07 セルトリックス　ファーマシューティカルズ，インコーポレイテッド β型トランスフォーミング成長因子
EP0513334A4 (en) * 1990-11-30 1993-08-04 Celtrix Laboratories, Inc. Use of a bone morphogenetic protein in synergistic combination with tgf--g(b) for bone repair
US5824647A (en) * 1990-12-12 1998-10-20 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US5436228A (en) * 1990-12-12 1995-07-25 Postlethwaite; Arnold E. Chemotactic wound healing peptides
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US5972884A (en) * 1991-03-11 1999-10-26 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US6399569B1 (en) * 1991-03-11 2002-06-04 Curis, Inc. Morphogen treatments for limiting proliferation of epithelial cells
US5300292A (en) * 1991-05-03 1994-04-05 The Regents Of The University Of California Composition and method for treating inflammation
CA2102808A1 (en) 1991-05-10 1992-11-11 Hanne Bentz Targeted delivery of bone growth factors
US7384634B2 (en) * 1991-08-30 2008-06-10 University Of South Florida Connective tissue growth factor
US6022853A (en) * 1991-08-30 2000-02-08 Creative Biomolecules, Inc. Morphogen-enriched dietary composition
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
WO1993022431A1 (en) * 1992-04-30 1993-11-11 Baylor College Of Medicine Constitutive and inducible epidermal vector systems
US5958764A (en) * 1992-04-30 1999-09-28 Baylor College Of Medicine Specific expression vectors and methods of use
US5322933A (en) * 1992-05-07 1994-06-21 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Crystal structure of TGF-β-2
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
US6180602B1 (en) * 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
US5420243A (en) * 1993-01-26 1995-05-30 Celtrix Pharmaceuticals, Inc. Biologically active TGF-β2 peptides
US5531791A (en) * 1993-07-23 1996-07-02 Bioscience Consultants Composition for repair of defects in osseous tissues, method of making, and prosthesis
US5763416A (en) * 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US6074840A (en) * 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US20020193338A1 (en) * 1994-02-18 2002-12-19 Goldstein Steven A. In vivo gene transfer methods for wound healing
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5614489A (en) * 1995-05-25 1997-03-25 Mohammadi; Fatemeh Method and composition for treating the skin
US6040431A (en) * 1995-06-07 2000-03-21 Stryker Corporation Single chain analogs of the TGF-β superfamily (morphons)
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
EP1364655B1 (de) 1996-03-22 2010-12-29 Stryker Corporation Verfahren zur verbesserten funktionellen Erholung der motorischen Koordiination, der Sprache oder der Sinneswahrnehmung nach Trauma oder Ischämie des ZNS
US5939069A (en) * 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
US6248723B1 (en) 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
US20020141995A1 (en) * 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
WO1999006563A1 (en) 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
NZ530481A (en) * 2001-06-07 2007-11-30 Skinmedica Inc Compositions comprising cell culture medium conditioned by cells grown in three-dimensional culture
US7431922B2 (en) * 2002-03-29 2008-10-07 Tissuegene, Inc. Bioadhesive directed somatic cell therapy
JP5128935B2 (ja) * 2004-03-31 2013-01-23 ジェネンテック， インコーポレイテッド ヒト化抗ＴＧＦ−β抗体
US7763257B2 (en) 2004-12-09 2010-07-27 Christina Juneau Compositions comprising transforming growth factor (TGF)-β1 and TGF-β2 in admixture of proteins obtained from dairy products

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400199A (en) * 1965-02-26 1968-09-03 Leslie L. Balassa Wound-healing cartilage powder
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4473551A (en) * 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition
DE3382562D1 (de) * 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
US4434094A (en) * 1983-04-12 1984-02-28 Collagen Corporation Partially purified osteogenic factor and process for preparing same from demineralized bone
AU3108984A (en) * 1983-06-03 1985-01-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Purified transforming growth factor-beta derived from human platelets and placentas
DE3588058T3 (de) * 1984-07-16 2005-04-07 Celtrix Pharmaceuticals, Inc., Palo Alto Knorpel-induzierende Polypeptid-Faktoren aus Knochen
EP0269408A3 (de) * 1986-11-26 1989-08-30 Genentech, Inc. TGF-Beta für die Behandlung von entzündlichen Erkrankungen

Also Published As

Publication number Publication date
AU6087586A (en) 1987-02-12
EP0213776A2 (de) 1987-03-11
EP0213776A3 (en) 1989-05-03
DE3687099T2 (de) 1993-03-18
AU591513B2 (en) 1989-12-07
JPH06228005A (ja) 1994-08-16
ATE82133T1 (de) 1992-11-15
EP0451439B1 (de) 1996-03-13
DE3650499T2 (de) 1996-07-25
ATE135231T1 (de) 1996-03-15
JPH0798754B2 (ja) 1995-10-25
DE3650499D1 (de) 1996-04-18
US4806523A (en) 1989-02-21
EP0213776B1 (de) 1992-11-11
CA1265445A (en) 1990-02-06
US5008240A (en) 1991-04-16
EP0451439A1 (de) 1991-10-16

Similar Documents

Publication Publication Date Title
DE3687099D1 (de) Verwendung von einem cartilago-induzierenden faktor (cif) zur herstellung eines arzneimittels zur behandlung von entzuendungen.
DE69333626D1 (de) Verwendung von Adamantan Derivaten zur Herstellung eines Medikaments zur GLAUKOMBEHANDLUNG
DE69332624D1 (de) WUNDHEILMITTEL UND BEHANDLUNG VON FIBROTISCHEN STORUNGEN DURCH TGFbeta-3
ATE127342T1 (de) Verwendung von modafinil zur herstellung eines antiischämischen arzneimittels.
AU2490297A (en) Use of strontium salts for the production of pharmaceutical compositions intended for the treatment of arthrosis
MY141415A (en) Therapeutic combination containing interferon
GEP20002300B (en) Purified Forms of Dnase, Method for Its Production, Pharmaceutical Composition and Use Thereof
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69421778D1 (de) Verwendung von wirksamen Mengen von aktiven Stoffen zur Behandlung von Mischhaut
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE99932T1 (de) Verwendung von pyrrolicloncarbonsaeurealkylestern zur herstellung eines arzneimittels zur behandlung von ichtyosis.
ATE218857T1 (de) Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
ATE63815T1 (de) Verwendung von zinn-protoporphyrin und zinnmesoporphyrin zur herstellung eines arzneimittels fuer die behandlung von psoriasis.
DE3582594D1 (de) Proglumid und dessen pharmazeutische zusammensetzungen zur anwendung bei der behandlung von neoplastischen affektionen.
PH18061A (en) Anti-inflammatory and/or analgesic 2,3-diaryl-5-halo thiophenes
ATE75144T1 (de) Verwendung einer waessrigen chloritmatrix-loesung zur herstellung von arzneimitteln zur intravenoesen behandlung von tumoren.
DE69600367D1 (de) Verwendung von Sulfasalazin und/oder dessen aktiven Metaboliten zur Herstellung eines Arzneimittels zur Behandlung von venöser Insuffizienz und venösen Ulcera
ATE234613T1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DE68916777D1 (de) Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.
GR3019819T3 (en) Use of wild garlic for the therapy or prevention of blood circulation disturbances.
ATE107166T1 (de) Verwendung von chlormethiazol zur herstellung eines artzneimittels zur prophylaxe oder therapie der neurodegeneration.
AU1691888A (en) Compound active in cardiovascular therapy
DE69311286D1 (de) Verwendung von Melatonin zur Herstellung eines Arzneimittels zur Behandlung von Scleroderma und der Sarcoidosis
ATE36333T1 (de) Hydantoin enthaltende therapeutische mittel.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee